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Recent research has elucidated circulating levels of almost all factor H-related (FHR) 
proteins. Some of these proteins are hypothesized to act as antagonists of the
important complement regulator factor H (FH), fine-tuning complement regulation on 
human surfaces. For the CFHR4 splice variants FHR-4A and FHR-4B, the individual 
circulating levels are unknown, with only total levels being described. Specific reagents 
for FHR-4A or FHR-4B are lacking due to the fact that the unique domains in FHR-4A 
show high sequence similarity with FHR-4B, making it challenging to distinguish them. 
We developed an assay that specifically measures FHR-4A using novel, well-character-
ized monoclonal antibodies (mAbs) that target unique domains in FHR-4A only. Using 
various FHR-4A/FHR-4B-specific mAbs, no FHR-4B was identified in any of the serum 
samples tested. The results demonstrate that FHR-4A is the dominant splice variant 
of CFHR4 in the circulation, while casting doubt on the presence of FHR-4B. FHR-4A 
levels (avg. 2.55 ± 1.46 µg/mL) were within the range of most of the previously reported 
levels for all other FHRs. FHR-4A was found to be highly variable among the population, 
suggesting a strong genetic regulation. These results shed light on the physiological 
relevance of the previously proposed role of FHR-4A and FHR-4B as antagonists of FH 
in the circulation.
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inTrODUcTiOn
The complement system is an evolutionarily ancient protein cascade which, through a series of 
events, recognizes, attacks, and kills foreign cells like bacteria, but can also target host cells [reviewed 
by Ricklin et  al. (1)]. In order to prevent damage of healthy host cells, humans possess several 
complement regulators. Some are membrane bound and expressed on the cell surface; however, 
one of the most important regulators, complement factor H (FH) circulates freely in plasma. FH 
is a 155 kDa glycoprotein that circulates in blood with a reported average concentration ranging 
from 233 up to 400 µg/mL or 1.5–2.6 µM (2–6). FH is a crucial regulator of the alternative acti-
vation pathway of the complement system, orchestrating complement activation toward foreign 
cells by specifically binding to and inhibiting complement on human cells. FH belongs to the FH 
FigUre 1 | Characterization of anti-FHR-4A monoclonal antibodies (mAbs). (a) Cross-reactivity of the anti-FHR-4A mAbs to biotinylated rhFHR proteins and 
biotinylated plasma-derived FH was determined by ELISA. (B) Schematic representation of FHR-4A, FHR-4B, and the recombinant fragments of FHR-4A used  
for epitope mapping, with the duplicated SCR domains in FHR-4A depicted in black. Corresponding percentage of sequence identity between the domains in 
FHR-4A is indicated. Domains 1 and 6–9 of FHR-4A are completely identical to the domains of FHR-4B (indicated by gray shading). (c) Epitope mapping of 
anti-FHR-4A antibodies using the fragments of rhFHR-4A as depicted in (B), determined by ELISA. As a control, polyclonal anti-FHR-3 (poly), which cross-reacts 
with all FHR proteins was used. (D) Schematic representation of the epitope location of each of the anti-FHR-4A mAbs. Single epitope mAbs are listed above 
FHR-4A, mAbs with multiple epitopes below. Note that most cross-reactive mAbs have two epitopes in FHR-4A, due to the high sequence similarity of the SCR 
domains. (e) Competition ELISA with monospecific mAbs (anti-FHR-4A.02 and 4A.04) and cross-reactive mAbs (anti-FHR-4A.08 and 4A.11). Binding of biotinylated 
rhFHR-4A is expressed as relative to the binding of biotinylated rhFHR-4A without any competing mAb. Bars represent mean of independent replicates with error 
bars indicating SD. All graphs are representative of multiple independent experiments.
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protein family, which consists of eight proteins derived from 
six genes, encoded in tandem in the CFH locus. The CFH gene 
itself encodes two proteins, FH and its splice-variant FH-like 
1 (FHL-1). Next to FH and FHL-1, six factor H-related (FHR) 
proteins are found in plasma. Like FH and FHL-1, the FHRs are 
completely comprised of domains called short consensus repeat 
(SCR) domains. FHR-1, FHR-2, FHR-3, and FHR-5 are encoded 
separately by corresponding genes (CFHR1, CFHR2, CFHR3, 
and CFHR5), while FHR-4A and FHR-4B are splice variants 
encoded by CFHR4 (7, 8). FHR-4A is the largest FHR (86 kDa) 
and comprises nine SCR domains, while FHR-4B has been pre-
dicted to consist of five SCR domains (43 kDa) (7, 8). The five 
SCR domains of FHR-4B are completely identical to SCR 1 and 
SCRs 6–9 of FHR-4A (Figure 1B). The unique four SCR domains 
between SCRs 1 and 6 of FHR-4A appear to have arisen from an 
internal duplication in CFHR4 and are highly similar to the other 
SCR domains in FHR-4A and, therefore, also to FHR-4B (8). SCR 
1 is highly similar to SCR 5 (85%), 2–6 (90%), 3–7 (93%), and 
SCR 4 to SCR 8 (87%) in FHR-4A. This makes it challenging to 
specifically distinguish FHR-4A from FHR-4B in immunoassays.
It is still unclear what the role of FHR-4A and FHR-4B is 
within the complement system. Increasing evidence indicates 
that FHRs act as antagonists of FH, competing with FH for the 
binding to complement C3b and human cell surfaces [reviewed 
by Józsi et al. (9)]. FHR-4A and -4B seem to lack physiologically 
relevant complement inhibitory activities on their own. FHR-4A 
has been reported to enhance the co-factor activity of FH at sup-
raphysiological concentrations (10, 11). Furthermore, binding of 
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FHR-4A and FHR-4B instead of FH allows complement activa-
tion to occur on the surface (11) and FHR-4A and FHR-4B might 
act as a competitor of FH. This form of regulation might serve 
to fine-tune complement inhibition by FH on surfaces where 
balanced complement activation is required for clearance, such 
as on necrotic and apoptotic cells. This hypothesis would also 
explain associations between genetic variation in CFHR genes 
and various diseases. For instance, the lack of CFHR3 and CFHR1 
due to copy number variation (CNV) has been repor ted to be 
protective against age-related macular degeneration (12,  13). 
However, no such link with disease has yet been found for 
CFHR4. Like other FHRs, FHR-4A and FHR-4B bind to C3b and 
C-reactive protein, allowing complement activation to occur (11, 
14, 15). Furthermore, FHR-4A has been reported to recruit CRP 
to necrotic cells in vitro, allowing more complement activation 
to occur, and is found to be accumulated in necrotic tissue (14). 
However, in contrast to all other members of the FH protein 
family, FHR-4A and FHR-4B seem to lack any affinity toward 
heparin (16, 17).
Highly relevant for the proposed antagonistic properties of 
FHR proteins is their physiological concentration, especi ally 
in relation to FH. Recently, we have reported normal pro tein 
conc entrations for all FHRs in >100 healthy individuals, except 
for FHR-4A and FHR-4B. FHR-1/1 homodimers, FHR-2/2 
homodimers, and FHR-1/2 heterodimers circulate at average 
concentrations of 14.6 (±3.0), 0.7 (±0.4), and 5.8 (±2.4) μg/mL, 
respectively, in healthy donors with two CFHR1 copies, whereas 
FHR-5/5 homodimers circulate at 1.7 (±0.4) μg/mL in healthy 
donors (18). Of note, the FHR-1 total levels have recently also 
been reported to be 122 (±26) μg/mL, without distinguishing 
between homo- or heterodimers, nor fully describing the cali-
bration used (19). However, a third, independent, group recently 
reported combined, total FHR-1, FHR-2, and FHR-5 levels, 
measured in an immunoassay, to be 10.7 (±5.4) μg/mL, thus 
supporting the lower levels for FHR-1 and FHR-2 (20). FHR-3 
circulates at average concentrations of 0.7–1.1 µg/mL (6, 21). For 
FHR-4A and FHR-4B, only total FHR-4 levels ranging from 6.5 
to 53.9 µg/mL with an average concentration of 25.4 µg/mL have 
been described, measured in only 11 healthy individuals (11). 
These levels were determined without distinguishing between 
FHR-4A and FHR-4B. Therefore, in order to specifically measure 
FHR-4A and FHR-4B, as well as establishing normal levels in a 
larger cohort of healthy individuals, we have developed specific 
reagents for FHR-4A and FHR-4B. Monoclonal antibodies (mAbs) 
were used to specifically detect FHR-4A, but we were unable to 
detect any freely circulating FHR-4B in human serum, despite the 
use of various cross-reactive mAbs. Finally, we demonstrate that 
FHR-4A levels vary greatly among healthy individuals.
MaTerials anD MeThODs
samples
Healthy donor serum samples were collected as part of a previous 
study from anonymous, healthy volunteers with informed, written 
consent in accordance with Dutch regulations and this study was 
approved by the Sanquin Ethical Advisory Board in accordance 
with the Declaration of Helsinki (6). Normal human serum (NHS) 
pool comprises serum from 400 healthy donors. FHR-3-deficient 
serum pool comprises serum of four healthy donors previously 
genotyped by multiplex ligation-dependent probe amplification 
to carry no CFHR3 gene copies (6). Samples of patients with con-
firmed bacterial infections were collected as part of the EUCLIDS 
project (van Beek et al., manuscript in preparation). CRP levels 
were determined in these samples as part of routine testing.
Proteins and reagents
Rat anti-mouse kappa (RM-19) mAb was from Sanquin Reagents 
(Sanquin, Amsterdam, the Netherlands). High-performance 
ELISA buffer (HPE) was provided by Sanquin. Proteins were 
biotinylated according to the manufacturer’s instructions using 
EZ-Link Sulfo-NHS-LC-Biotin, No-Weigh Format (Thermo 
Scientific, Waltham, MA, USA), when indicated. Polyclonal anti-
FHR-3 antibodies and mAb clone anti-FHR-3.3 were obtained 
and characterized as part of a previous study (6). Recombinant 
human (rh) FHR proteins, containing a C-terminal 6×-histidine 
tag, were produced and purified as previously described (6). 
In short, proteins were expressed by transient transfection of 
pcDNA3.1 expression vectors in HEK293F cells, after which 
proteins were purified from the supernatant by Ni2+ affinity chro-
matography using HisTrap™ High Performance 1 mL columns 
(GE Healthcare Life Sciences, Freiburg, Germany). rhFHRs were 
filtered and concentrated using Amicon® Ultra Centrifugal Filter 
Devices (Merck Millipore, Darmstadt, Germany) according to 
the manufacturer’s instructions using appropriate molecular 
weight cut-offs. For rhFHR-4A, a 100 kDa cut-off Amicon® Filter 
was used to further purify rhFHR-4A from any high molecular 
weight aggregates observed after Ni2+ affinity chromatography 
purification (Figures S1A,B in Supplemental Material).
immunization, mab generation,  
and characterization
Anti-FHR-4A mAbs were generated, screened, and purified 
as previously described, using rhFHR-4A as immunogen (6). 
Isotypes of mAbs were determined by ELISA or with the use 
of the Mouse mAb Isotyping Kit (Hycult Biotech, Uden, the 
Netherlands) according to the manufacturer’s instructions. 
Cross-reactivity against other FH protein family members was 
determined as previously described (6).
epitope Mapping
The epitope location of each of the anti-FHR-4A mAbs was 
determined using rhFHR-4A, rhFHR-4B, and rhFHR-4A frag-
ments consisting of SCR domains 1–3, 2–4, 4–9, 5–7, or 8–9 as 
previously described (15). Proteins and fragments were coated 
(4 µg/mL in PBS) onto Nunc Maxisorp 96-well microtiter plates 
(Invitrogen, Life Technologies, Carlsbad, CA, USA) by over-
night (O/N) incubation at 4°C. Plates were washed three times 
with PBS + 0.02% (w/v) Tween-20 (PT) and blocked with 4% 
(w/v) BSA in PBS by incubation for 1 h. After another wash with 
PT, wells were incubated with the anti-FHR-4A mAbs diluted 
in PT for 1 h. Unbound anti-FHR-4A mAbs were washed away 
by washing the wells five times with PT, followed by incubat-
ing with 0.05% (v/v) HRP-conjugated rabbit anti-mouse IgG 
(Dako Agilent, Santa Clara, CA, USA) for 1 h and subsequently 
4Pouw et al. FHR-4A Levels in Human Serum
Frontiers in Immunology | www.frontiersin.org April 2018 | Volume 9 | Article 729
washing the plates five times. The ELISA was developed using 
3,5,3′,5′-tetramethylbenzidine (TMB) solution and the reac-
tion was stopped using 50 µL 2 M H2SO4. As a positive control, 
FHR-4A fragments were detected using polyclonal rabbit anti- 
FHR-4A, followed by HRP-conjugated goat anti-rabbit IgG 
(Dako Agilent). All ELISA steps were performed with a final 
volume of 50 µL per well and incubated at room temperature 
while shaking unless stated otherwise. Absorption was measured 
at 450 nm and corrected for background absorbance at 620 nm.
competition elisa
To determine whether the mAbs competed for the binding of 
rhFHR-4A, Nunc Maxisorp 96-well microtiter plates (Invitrogen) 
were coated with 100 µL of 2 µg/mL anti-FHR-4A mAbs, in PBS, 
by incubating O/N at room temperature. Next, the plates were 
washed with PT. Biotinylated rhFHR-4A (0.1  µg/mL, in HPE) 
was incubated with 10 µg/mL of each mAb for 20 min, followed 
by incubation on the washed plate for 1  h. Next, unbound 
biotinylated rhFHR-4A was washed away and the wells were 
incubated with 0.01% (v/v) strep-poly-HRP (Sanquin), diluted 
in HPE, for 20 min. After washing, the assay was developed by 
addition of 100 µL of 100 µg/mL TMB in 0.11 M sodium acetate 
containing 0.003% (v/v) H2O2, pH 5.5. Substrate conversion was 
stopped after approximately 10 min by addition of 100 µL 2 M 
H2SO4. Absorbance was measured at 450 nm and corrected for the 
absorbance at 540 nm with a Synergy 2 Multi-Mode plate reader 
(BioTek Instruments, Winooski, VT, USA). All ELISA steps were 
performed with a volume of 100  µL per well and incubated at 
room temperature while shaking unless stated otherwise.
sucrose gradient
Sucrose gradients were described previously (18). In short, NHS 
or FHR-3-deficient serum (150  µL of 50%, v/v, pooled serum, 
diluted in PBS) were loaded on 5–32.9% (w/v) sucrose (Merck 
1.07654) gradients. Gradients were centrifuged for 20  h at 
160,000 ×  g after which they were fractionated in 24 fractions 
of 500 µL. Proteins were immunoprecipitated and visualized on 
Western Blots as described below.
immunoprecipitation (iP)
Factor H-related-4A and FHR-4B were immunoprecipitated from 
human healthy donor serum or sucrose gradient fractions using 
indicated mAbs. IP was performed by incubating 200 µL serum 
or 250  µL sucrose gradient fraction with 500  µL of 5  mg/mL 
CNBr-activated sepharose (GE Healthcare, Little Chalfont, UK) to 
which RM-19 was coupled (25 mg mAb per 1 g sepharose), and 
50 µL of 100 µg/mL mAb, diluted in PBS supplemented with 0.1% 
Tween-20, 0.1% BSA, and 10  mM EDTA. Following overnight 
incubation at 4°C, while rotating, the sepharose was washed three 
times with 1 mL PT and two times with 1 mL PBS. Precipitated pro-
teins were eluted by addition of 50 µL 1× NuPAGE Sample buffer 
solution (Invitrogen) and incubation at 70°C for 10  min. After 
spinning down the sepharose, SDS-PAGE under non-reducing 
conditions was performed using a Novex NuPAGE 10 or 4–12% 
Bis–Tris gel followed by Western Blot onto a nitrocellulose mem-
brane (Novex iBlot Gel Transfer kit, Invitrogen). Membranes were 
blocked with 1% (v/v) Western Blocking Reagent (WBR) (Roche, 
Basel, Switzerland) in PBS for 30 min and incubated with 1 µg/mL 
biotinylated polyclonal rabbit anti-FHR-3 in PBS +  0.5% (v/v) 
WBR, O/N. After washing three times with PT, membranes were 
incubated with 0.1% (v/v) Strep-HRP in PBS + 0.5% (v/v) WBR. 
After 1 h, the membranes were washed three times with PT fol-
lowed by two washes with PBS. Western Blots were developed with 
the Pierce ECL 2 Western Blotting substrate kit (Thermo Scientific) 
according to the manufacturer’s instructions and analyzed using 
the ChemiDoc™ MP System (BioRad, Hercules, CA, USA).
Fhr-4a elisa
To measure FHR-4A in serum, RM-19 was coated (3 µg/mL in PBS) 
onto Nunc Maxisorp 96-well microtiter plates (Invitrogen) by O/N 
incubation at room temperature. After coating, plates were washed 
five times with PT, followed by incubation with 1 µg/mL anti-FHR-
4A.04 in HPE, for 1 h. After washing, samples, diluted in HPE, were 
added and incubated for 1 h. Following washing with PT, 0.5 µg/mL 
biotinylated polyclonal anti-FHR-3 (in HPE) was incubated on the 
plate for 1 h. Next, unbound conjugate was washed away and the 
wells were incubated with 0.01% (v/v) strep-poly-HRP (Sanquin), 
diluted in HPE, for 20 min. After washing, the assay was developed 
as described above using TMB and measuring absorbance at 
450 nm and correcting for the absorbance at 540 nm. All ELISA 
steps were performed with a volume of 100 µL per well and incub-
ated at room temperature while shaking unless stated otherwise. 
For the calibration of the FHR-4A ELISA, highly pure rhFHR-4A 
was used (Figure S1B in Supplemental Material) of which the con-
centration was determined by measuring the absorbance at 280 nm 
and using an absorbance coefficient of 2.134 (0.1% w/v solution).
statistical analysis
Analysis and statistical tests were performed using GraphPad 
Prism, version 7.03 (GraphPad Software, La Jolla, CA, USA).
resUlTs
characterization of mabs against Fhr-4a
We characterized 13 mouse mAbs raised against rhFHR-4A. 
All mAbs were first tested for cross-reactivity against all other 
members of the FH protein family (Figure 1A). The mAbs were 
named in order of increasing cross-reactivity: anti-FHR-4A.01 to 
4A.06 being mono-specific for rhFHR-4A, anti-FHR-4A.07, and 
4A.08 recognizing both rhFHR-4A and -4B, anti-FHR-4A.09 to 
4A.11 recognizing rhFHR-3, 4A, and -4B, anti-FHR-4A.12 binding 
rhFHR-2, -3, -4A, and -4B, whereas anti-FHR-4A.13 recognizes all 
rhFHRs except rhFHR-5. None of the anti-FHR-4 mAbs showed 
cross-reactivity with either FHR-5 or FH.
With the use of recombinant fragments comprising different 
FHR-4A domains (Figure  1B), the epitope location of almost 
all anti-FHR-4A mAbs were mapped. As expected, all FHR-4A-
specific mAbs (anti-FHR-4A.01 to 4A.06) bound to an epitope 
located in domains 2–5, which are unique for rhFHR-4A and not 
present in rhFHR-4B (Figures 1C,D). Of these FHR-4A specific 
mAbs, only anti-FHR-4A.04 recognized an epitope located in 
domain 5, whereas all other mAbs bound to an epitope in domain 2 
or 3. Anti-FHR-4A.01, 4A.02, 4A.03, 4A.05, and 4A.06, competed 
TaBle 1 | Anti-factor H-related (FHR)-4A monoclonal antibodies characterized in this study.
epitope location (domain)
Designation Mouse isotype 1st 2nd cross-reactivity competes with
Anti-FHR-4A.01 IgG1, Kappa 2–3 – None 4A.02, 4A.03, 4A.05, 4A.06
Anti-FHR-4A.02 IgG1, Kappa 2–3 – None 4A.01, 4A.03, 4A.05, 4A.06
Anti-FHR-4A.03 IgG1, Kappa 2–3 - None 4A.01, 4A.02, 4A.05, 4A.06
Anti-FHR-4A.04 IgG1, Kappa 5 – None None
Anti-FHR-4A.05 IgG2b, Kappa 2–3 – None 4A.01, 4A.02, 4A.03, 4A.06
Anti-FHR-4A.06 IgG1, Kappa 2–3 – None 4A.01, 4A.02, 4A.03, 4A.05
Anti-FHR-4A.07 IgG1, Kappa 2–3 6–7 rhFHR-4B None
Anti-FHR-4A.08 IgG1, Kappa 1 5 rhFHR-4B 4A.01, 4A.02, 4A.03, 4A.05, 4A.06
Anti-FHR-4A.09 IgG1, Kappa 8–9 – rhFHR-3, -4B None
Anti-FHR-4A.10 IgG1, Kappa 4 8 rhFHR-3, -4B None
Anti-FHR-4A.11 IgG1, Kappa 2–3 6–7 rhFHR-3, -4B 4A.01, 4A.02, 4A.03, 4A.05, 4A.06
Anti-FHR-4A.12 IgG1, Kappa 4 8 rhFHR-2, -3, -4B None
Anti-FHR-4A.13 IgG1, Kappa Unknown Unknown rhFHR-1, -2, -3, -4B 4A.09
FigUre 2 | Immunoprecipitation (IP) of plasma-derived factor H-related (FHR) proteins by the anti-FHR-4A monoclonal antibodies (mAbs). (a) Western blot 
following IP from pooled normal human serum using the indicated mAbs. For comparison, 100 ng rhFHR-4A and rhFHR-4B were loaded on the left side of the gel. 
Precipitated proteins are indicated with arrowheads on the right side of the blot. (B) As in (a), but with pooled serum of healthy donors who are deficient for CFHR3 
and CFHR1 and using only the cross-reactive anti-FHR-4A mAbs for IP. (c) IP using polyclonal anti-FHR-3 and serum of two healthy donors with either two CFHR3 
(CFHR3 suf.) or no CFHR3 (CFHR3 def.) gene copies. All Western blots were stained with cross-reactive biotinylated polyclonal anti-FHR-3. Precipitated proteins are 
indicated with arrowheads on the right side of each blot. Results are representative of multiple independent experiments.
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with each other for the binding of rhFHR-4A, indicating identical 
or partially overlapping epitopes (data not shown).
Of the mAbs that cross-reacted with rhFHR-4B and other 
FHR protein family members, most appeared to bind to either of 
two epitopes in rhFHR-4A, reflecting the high degree of similar-
ity between these SCR domains 2–5 in FHR-4A and the domains 
1, 6, 7, and 8 in FHR-4A and FHR-4B.
Only anti-FHR-4A.09 appeared to have one epitope in domain 
8 or 9, recognizing both rhFHR-4A and rhFHR-4B, while also 
cross-reacting with FHR-3.
The cross-reactive mAbs anti-FHR-4A.08 and anti-FHR-
4A.11 were able to block binding of rhFHR-4A to the mono-
specific FHR-4A mAbs; however, in the reverse setting, this 
cross-blocking was not achieved (Figure 1E). This is in line with 
the presence of two epitopes for anti-FHR-4A.08 and 4A.11 in 
rhFHR-4A. It indicates that one of the two epitopes for anti-FHR-
4A.08 and anti-FHR-4A.11 is partially overlapping or sterically 
hindering the binding site of the monospecific mAbs. The epitope 
location of anti-FHR-4A.13 could not be mapped due to a very 
low and ambiguous binding signal when the fragments were 
used. However, binding of rhFHR-4A to anti-FHR-4A.13 could 
be blocked with anti-FHR-4A.09, suggesting an epitope location 
in either domain 8 or 9 for anti-FHR-4A.13. An overview of 
the mAbs characteristics, the mapped epitope location, and the 
cross-reactivity is given in Table 1.
Only Fhr-4a is Detected in nhs
Next, we tested whether the anti-FHR-4A mAbs capture FHR-4A 
and FHR-4B from NHS. To this end, an IP followed by Western 
Blot was performed, which was developed with cross-reactive 
biotinylated polyclonal anti-FHR-3. Of the specific anti-FHR-4A 
mAbs, only anti-FHR-4A.04 seemed to efficiently capture FHR-4A 
from NHS, resulting in a clear protein band corresponding to 
the molecular weight of FHR-4A (86 kDa) (Figure 2A). Only a 
very faint FHR-4A band was visible in the precipitates of anti- 
FHR-4A.01, 4A.02, 4A.03, 4A.05, and 4A.06. In addition, both 
anti-FHR-4A.07 and anti-FHR-4A.13 were neither able to 
efficiently immunoprecipitate FHR-4A from serum nor any 
of the other FHR proteins with which these mAbs cross-react. 
A band corresponding to FHR-4B (43  kDa) in the IP with 
FigUre 3 | Sucrose gradients of normal human serum (NHS) and CFHR3-deficient serum. Western Blots of immunoprecipitation (IP) of fractions (1–24)  
from a sucrose gradient with (a) NHS or (B) a serum pool deficient for FHR-3 (CFHR3−/−). IP was performed using anti-FHR-3.3, Western Blots were stained  
with biotinylated polyclonal anti-FHR-3 antibody. Fractions containing IgM (970 kDa, fractions 3–7), IgG (150 kDa, fractions 15–17), or albumin (66 kDa,  
fractions 17–21) are indicated above the blots and used as size reference. Identified proteins are indicated with arrowheads on the right side.
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anti-FHR-4A.08 also appeared to be missing, while the mAb was 
found to be cross-reactive with rhFHR-4B in the ELISA. A pro-
tein band corresponding to FHR-4B could not be distinguished 
in the IP of anti-FHR-4A.09 to anti-FHR-4A.12, as these mAbs 
also precipitated FHR-3 (43–50 kDa), which migrates at the same 
expected molecular weight and is also recognized by the poly-
clonal anti body. Therefore, to better visualize the IP of FHR-4B, 
an IP from a FHR-3-deficient serum pool was performed, using 
the cross-reactive mAbs. However, also in these conditions, 
no band corresponding to FHR-4B was detected in the IP of 
anti-FHR-4A.08 to anti-FHR-4A.12, which was unexpected 
given the cross-reactivity we observed with rhFHR-4B in ELISA 
(Figure 2B). On the other hand, anti-FHR-4A.12 did immuno-
precipitate FHR-2 from NHS, confirming the cross-reactivity 
results obtained with rhFHR-2. As a control, the IP was repeated 
with the cross-reactive polyclonal anti-FHR-3 using serum of two 
healthy donors, one with two CFHR3 gene copies, and one with no 
CFHR3 gene copies. This resulted in the precipitation of FH, 
FHL-1, FHR-3, and FHR-4A (Figure 2C). However, also with this 
set-up, no FHR-4B was detected.
Serum fractionated by sucrose gradients was previously used 
to investigate the molecular size of FHR proteins in their native 
state (18). Using a recently characterized anti-FHR-3 mAb that 
cross-reacts with FH, rhFHR-4A, rhFHR-4B, and FHL-1 (clone 
anti-FHR-3.3) (6), we investigated the circulating molecular size 
of FHR-4A relative to FH and FHR-3, by IP of these proteins 
from sucrose gradient fractions. As expected, FH was precipitated 
from the fractions also containing IgG, while FHR-3 was mainly 
present in the fractions containing albumin, corresponding with 
their respective molecular weights (155 and 50 kDa) (Figure 3A). 
FHR-4A was found in the fractions corresponding with its 
molecular weight (86 kDa), between the main fractions contain-
ing FH and FHR-3. Again, no bands corresponding with FHR-4B 
were found in the sucrose gradient fractions of neither the FHR-3 
sufficient nor the FHR-3-deficient serum pool (Figure 3B).
Fhr-4a levels Vary greatly Between 
individuals
As we could not detect FHR-4B in human serum, we next 
focused on specifically measuring FHR-4A by ELISA. FHR-4A 
was measured using the monospecific mAb anti-FHR-4A.04, 
captured on immobilized RM-19, and using biotinylated 
polyclonal anti-FHR-3 antibody as a conjugate. The specificity 
FigUre 4 | Development of the factor H-related (FHR)-4A specific ELISA. (a) Representative result on the reactivity of the FHR-4A ELISA against rhFHR proteins 
and plasma-derived FH. Anti-FHR-4A.04 was used as monospecific catching mAb, and binding of antigen was detected using cross-reactive polyclonal anti- 
FHR-3. (B) Calibration of pooled normal human serum using rhFHR-4A (10 µg/mL) in the FHR-4A ELISA. (c) Comparison of FHR-4A levels in seven paired serum 
and EDTA plasma samples using the FHR-4A ELISA. Each point represents the mean of three independent measurements per sample. (D) Effect of multiple freeze/
thaw cycles. Each point represents the mean of three independent measurements per sample with error bars indicating SD. Dashed lines indicate 90–110% range. 
(e) Concentration of FHR-4A in 129 healthy donor sera, measured by ELISA. Each point represents the mean of three independent measurements per serum 
sample. Line indicates mean with SD. (F) Scatter plot of FHR-4A levels versus CRP levels determined in 78 patients with acute bacterial infection. Correlation  
was assessed using Spearman’s correlation test.
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of the FHR-4A ELISA was confirmed using rhFHR proteins 
and plasma purified FH, giving a clear signal for rhFHR-4A 
(Figure 4A). Both rhFHR-3 and rhFHR-4B were detected at the 
highest concentrations we tested, but the FHR-4A ELISA was 
found to be 843-fold and 1,490-fold more sensitive for rhFHR-
4A compared to rhFHR-4B or rhFHR-3, respectively. Next, using 
purified rhFHR-4A, we calibrated a NHS pool to contain 2.33 µg/
mL FHR-4A, which was subsequently used as a calibration curve 
in the FHR-4A ELISA (Figure  4B). FHR-4A levels in serum 
and plasma did not differ (Figure 4C, P >  0.05), nor were the 
levels affected by repeated freeze/thaw cycles (Figure 4D). Next, 
we measured the levels of FHR-4A in serum from 129 healthy 
donors. The average concentration of FHR-4A was found to 
be close to the concentration found in the NHS pool, being 
2.55 µg/mL or 29.65 nM. Moreover, FHR-4A levels were found 
to be highly variable with a SD of 1.46 µg/mL and ranging from 
0.26 up to 6.20  µg/mL (Figure  4E). We subsequently investi-
gated whether FHR-4A behaves as an acute phase protein. To 
this end, we measured FHR-4A levels in 78 patients during an 
acute bacterial infection. No correlation was found for FHR-4A 
with CRP levels (r = 0.024, P = 0.834, Figure 4F). Of note, no 
total deficiency for FHR-4A was found in any healthy donor or 
patient measured during this study.
DiscUssiOn
The FHR proteins are hypothesized to act as antagonists of 
complement regulator FH, competing for binding to ligands and 
allowing, instead of inhibiting, complement activation on surfaces 
(9). Several reports have shown that recombinant FHR-4A and -4B 
indeed bind to known FH ligands and allow complement activa-
tion to occur in vitro (11, 14, 15). To date, normal levels of FHR-1, 
FHR-2, FHR-3, and FHR-5 have been reported and were found 
to be circulating at much lower concentration as compared to FH 
(6, 18, 21, 22). In this report, we describe the circulating levels 
of FHR-4A in healthy individuals, using novel, well-characterized 
anti-FHR-4A mAbs. FHR-4B is apparently absent in blood, imply-
ing that FHR-4A is the dominant splice variant of CFHR4.
We obtained thirteen mAbs that were raised against rhFHR-
4A, of which, six were found to be monospecific for FHR-4A. 
Their epitopes were mapped to be located within the four SCR 
domains unique for FHR-4A (and absent in FHR-4B). Of the 
seven cross-reactive mAbs that could also recognize the rhFHR-
4B protein, six mAbs were found to bind to two epitopes within 
rhFHR-4A, corresponding to SCR domains that share high 
sequence similarity within rhFHR-4A because of the known 
internal gene duplication. The presence of two epitopes for 
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these mAbs in rhFHR-4A was further supported by competition 
experiments. The rhFHR-4A-specific mAbs (one epitope) were 
not able to prevent binding of rhFHR-4A to cross-reactive mAbs 
(two epitopes), whereas the cross-reactive mAbs blocked binding 
to the specific mAbs, indicating that one of the two epitopes of the 
cross-reactive mAbs is overlapping with the epitope of the specific 
anti-FHR-4A mAbs.
Seven mAbs (anti-FHR-4A.01, -4A.02, -4A.03, -4A.05, 
-4A.06, -4A.07, and -4A.13) seemed unable or very inefficient 
in immunoprecipitating FHR-4A from NHS. The lack thereof is 
indicative for a much lower binding affinity for plasma-derived 
FHR-4A compared to rhFHR-4A. Strikingly, the epitopes of anti-
FHR-4A.01, -4A.02, -4A.03, -4A.05, -4A.06, and -4A.07 are all 
located in SCR domains of FHR-4A that contain (multiple) puta-
tive N-linked glycosylation sites. While rhFHR-4A is produced by 
HEK293F cells and thus possesses glycans from human origin, it 
is possible that differences in the exact glycan composition from 
those found in vivo are involved in the apparent lack of binding 
affinity toward serum-derived FHR-4A. This might also be the 
case for anti-FHR-4A.13, for which we could not precisely map 
the epitope location.
We were unable to identify a band corresponding to FHR-4B 
in the IP by five different cross-reactive mAbs against rhFHR-4A 
and rhFHR-4B. These mAbs were able to precipitate FHR-4A from 
serum. Because anti-FHR-4A.08, -4A.10, -4A.11, and -4A.12 all 
recognized two epitopes in rhFHR-4A, it is possible that the lack 
of FHR-4B detection following IP was caused by a difference 
in binding avidity, favoring FHR-4A over FHR-4B. However, 
anti-FHR-4A.09, which also did not precipitate FHR-4B from 
human serum, only recognized one epitope in domain 8/9 or 4/5 
of FHR-4A and FHR-4B, respectively. Thus far, only one report 
has suggested the presence of FHR-4B in human serum, being 
distinguished from FHR-3 by Western blotting following 2D 
electrophoresis separation (23). These blots were stained using 
cross-reactive polyclonal antibodies, making it unclear whether 
it is truly FHR-4B that was originally detected or not. Even if 
present, the levels of freely circulating FHR-4B must be extremely 
low compared to FHR-4A, since it was undetectable in any of 
our assays. Our current results are supported by previous reports, 
in which Western Blot analysis of human plasma also seems to 
indicate that FHR-4A is the dominant splice variant (8, 24). 
Hence, we developed an ELISA capable of specifically measuring 
FHR-4A and determined the normal average concentration of 
FHR-4A at 2.55 µg/mL (i.e., 29.65 nM). This is a 67.5-fold molar 
difference compared to the ~2 μM concentration of FH in human 
serum. The FHR-4A levels reported here are in line with previous 
reported levels determined by mass spectrometry (25) but stand 
in great contrast with the FHR-4 concentration of 25.4 µg/mL, 
as determined previously by an immunoassay (11). As discussed 
above, it seems unlikely that FHR-4B, which in theory was also 
measured in the previous report, can account for this difference. 
Both ELISAs catch FHR-4A with a monoclonal antibody while 
detecting it with a polyclonal antibody. Hence, it is more likely 
that there is a difference in the Sf9-derived rhFHR-4A previously 
used (14) and the HEK293F-derived rhFHR-4A used here for 
the calibration of the assays. Considering the recently reported 
normal values for all other FHR proteins (6, 18, 21, 22), ranging 
from 0.7 to 12 µg/mL (with FHR-1 being the most abundant FHR 
protein), it seems the values that we report for FHR-4A are likely 
to be correct.
We found considerable variation in FHR-4A concentra-
tion among healthy individuals, which is in line with previous 
observations by others (8, 17). This high degree of variation 
is also found in FHR-3 (6). However, the variation in FHR-3 
levels can, to a major extent, be explained by the CFHR3/CFHR1 
deletion, which is relatively common with an allele frequency 
of about 20% in the Western population (12, 13, 26–30). The 
second known deletion in the CFH-CFHR locus, encompassing 
CFHR1 and CFHR4, is far less common with an allele frequency 
of about 0.9% in the Western population (31). Thus, it is unlikely 
that CNV of CFHR4 explains the variation seen in FHR-4A 
levels, suggesting that other as yet unknown genetic variations 
determine the concentrations of FHR-4A, which is independ-
ent of inflammation since FHR-4A did not behave as an early 
acute phase protein. Studies investigating the genetic variation(s) 
resulting in altered FHR-4A expression are currently ongoing.
In summary, we characterized novel anti-FHR-4A mAbs, 
which were employed to develop a highly specific FHR-4A ELISA. 
FHR-4A was found to be the dominant splice variant of CFHR4 
and circulates in healthy individuals at an average concentration 
of 2.55 (±1.46) μg/mL. Similar to the other FHR proteins, the 
circulating levels of FHR-4A are much lower as compared to FH 
(~0.03 versus ~2 μM, respectively).
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